Cargando…
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2
MicroRNA-184 suppresses cell growth and survival via targeting c-Myc and Bcl- 2. We recently reported that miR-184 promotes tumor progression in non-small cell lung cancer via targeting CDC25A and c-Myc. We here hypothesized that miR-184 could be down-regulated by E6 oncoprotein to confer cisplatin...
Autores principales: | Tung, Min-Che, Lin, Po-Lin, Cheng, Ya-Wen, Wu, De-Wei, Yeh, Sauh-Der, Chen, Chi-Yi, Lee, Huei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078019/ https://www.ncbi.nlm.nih.gov/pubmed/27083050 http://dx.doi.org/10.18632/oncotarget.8708 |
Ejemplares similares
-
Expression of microRNA-184 in glioma
por: Wu, Xiao-Ben, et al.
Publicado: (2018) -
MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1
por: Lin, Bo-chuan, et al.
Publicado: (2016) -
Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
por: Tung, Min-Che, et al.
Publicado: (2015) -
MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2
por: Chen, Ming-Jenn, et al.
Publicado: (2018) -
microRNA-184 functions as tumor suppressor in renal cell carcinoma
por: SU, ZHENGMING, et al.
Publicado: (2015)